| 词条 | Phosphorylethanolamine |
| 释义 |
| Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 464205626 | ImageFile = Phosphorylethanolamine.svg | ImageSize = | IUPACName = 2-Aminoethyl dihydrogen phosphate | OtherNames = Phosphoethanolamine; PHOS |Section1={{Chembox Identifiers | CASNo_Ref = {{cascite|correct|CAS}} | CASNo = 1071-23-4 | UNII_Ref = {{fdacite|changed|FDA}} | UNII = 78A2BX7AEU | ChEMBL_Ref = {{ebicite|correct|EBI}} | ChEMBL = 146972 | PubChem = 1015 | ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} | ChemSpiderID = 990 | DrugBank_Ref = {{drugbankcite|changed|drugbank}} | DrugBank = DB01738 | ChEBI_Ref = {{ebicite|correct|EBI}} | ChEBI = 17553 | StdInChI_Ref = {{stdinchicite|correct|chemspider}} | StdInChI = 1S/C2H8NO4P/c3-1-2-7-8(4,5)6/h1-3H2,(H2,4,5,6) | StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} | StdInChIKey = SUHOOTKUPISOBE-UHFFFAOYSA-N | SMILES = C(COP(=O)(O)O)N | MeSHName = phosphorylethanolamine |Section2={{Chembox Properties | C = 2 | H = 8 | N = 1 | O = 4 | P = 1 | Appearance = White powder | Density = | MeltingPt = | BoilingPt = |Section3={{Chembox Hazards | MainHazards = | FlashPt = | AutoignitionPt = }}Phosphorylethanolamine or phosphoethanolamine is an ethanolamine derivative that is used to construct two different categories of phospholipids. One category termed a glycerophospholipid and the other a sphingomyelin, or more specifically within the sphingomyelin class, a sphingophospholipid. Phosphorylethanolamine is a polyprotic acid with two pKa values at 5.61 and 10.39.[1] Research{{medref|section|date=October 2016}}Research is being conducted with Ehrlich ascites tumor cells in vitro to see if phosphoethanolamine could be used in cancer treatment.[2] In studies in rats, phosphorylethanolamine failed to stop the growth of tumors.[3][4] There is, however, an experiment with mice that stated synthetic phosphoethanolamine has in vitro and in vivo anti-leukemia effects.[5] As a potential drug, phosphorylethanolamine in undergoing human clinical trials.[6] The main synthetic form of phosphorylethanolamine is calcium 2-aminoethylphosphate. LegalityThere has been ongoing controversy and litigation in Brazil with regard to its use as a cancer treatment without approval by the National Health Surveillance Agency. For years, Gilberto Chierice, a Chemistry Professor at the São Carlos campus of the University of São Paulo, used resources from a campus laboratory to unofficially manufacture, distribute, and promote the drug to cancer patients without it having gone through clinical testing. In September 2015, university administrators began preventing the Professor from continuing with this practice. In October 2015, several courts in Brazil ruled in favor of plaintiffs who wanted the right to try the compound. However, a state court overturned the lower courts' decision a month later. Jailson Bittencourt de Andrade, secretary for Brazil’s science and technology ministry, said the ministry plans to fund further research on the compound, but that it will be years before a determination can be made about phosphorylethanolamine's safety and efficacy in humans.[7][8] On April 14, 2016, a law was passed in Brazil allowing the use of synthetic phosphorylethanolamine for cancer treatment,[9] despite opposition from the Brazilian Medical Association, the Brazilian Society of Clinical Oncology, and the regulatory agency ANVISA.[10] However, shortly after, the country's Supreme Court suspended the law.[11] See also
References1. ^{{cite journal | author = Myller, AT | date = 2010 | title = Preparation of aminofunctionalized TiO2 surfaces by binding of organophosphates | journal = Applied Surface Science | volume = 257 | issue = 5 | pages = 1616|display-authors=etal | doi=10.1016/j.apsusc.2010.08.109| bibcode = 2010ApSS..257.1616M }} 2. ^{{Cite journal|title = Anticancer effects of synthetic phosphoethanolamine on Ehrlich ascites tumor: an experimental study|journal = Anticancer Research|date = 2012-01-01|issn = 1791-7530|pmid = 22213293|pages = 95–104|volume = 32|issue = 1|first = Adilson Kleber|last = Ferreira|first2 = Renato|last2 = Meneguelo|first3 = Alexandre|last3 = Pereira|first4 = Otaviano R.|last4 = Mendonça Filho|first5 = Gilberto Orivaldo|last5 = Chierice|first6 = Durvanei Augusto|last6 = Maria}} 3. ^{{cite news | url = http://plus55.com/business/2016/06/cancer-pill-fails-again | title = Cancer Pill Fails. Again. | date = June 2, 2016}} 4. ^{{cite news | url = http://www1.folha.uol.com.br/internacional/en/scienceandhealth/2016/06/1777072-effectiveness-of-cancer-pill-disproved-in-new-test.shtml | title = Effectiveness of 'Cancer Pill' Disproved in New Test | date = June 1, 2016}} 5. ^{{cite journal | last1 = Ferreira | first1 = A K | last2 = Santana-Lemos | first2 = B A A | last3 = Rego | first3 = E M | last4 = Filho | first4 = O M R | last5 = Chierice | first5 = G O | last6 = Maria | first6 = D A | year = 2013 | title = Synthetic phosphoethanolamine has in vitro and in vivo anti-leukemia effects | url = http://www.nature.com/bjc/journal/v109/n11/full/bjc2013510a.html | journal = British Journal of Cancer | volume = 109 | issue = | pages = 2819–2828 | doi = 10.1038/bjc.2013.510 | pmc = 3844899 }} 6. ^{{cite web |url=https://g1.globo.com/bemestar/noticia/fosfoetanolamina-instituto-do-cancer-suspende-testes-devido-a-ausencia-de-beneficio-clinico-significativo.ghtml |title=Fosfoetanolamina: Instituto do Câncer suspende novos testes devido a 'ausência de benefício clínico significativo' |date=31 March 2017 |access-date=10 January 2018 |language=Portuguese |trans-title=Phosphorylethanolamine: Cancer Institute suspends new tests due to 'lack of significant clinical benefits'}} 7. ^{{cite journal |url=http://www.nature.com/news/brazilian-courts-tussle-over-unproven-cancer-treatment-1.18864 |title=Brazilian courts tussle over unproven cancer treatment |volume=527 |issue=7579 |pages=420 |author=Heidi Ledford |date=24 November 2015 |work=Nature |doi=10.1038/527420a|bibcode=2015Natur.527..420L |pmid=26607521}} 8. ^{{cite journal |url=http://science.sciencemag.org/content/352/6281/18 |title=Brazil bill would legalize renegade cancer pill |volume=352 |issue=6281 |pages=18 |work=Science |doi=10.1126/science.352.6281.18|year=2016 |last1=Escobar |first1=H. |pmid=27034350}} 9. ^{{cite web |url=http://www.sciencemag.org/news/2016/04/brazil-president-signs-law-legalizing-renegade-cancer-pill |title=Brazil president signs law legalizing renegade cancer pill |author=Herton Escobar |date=14 April 2016 |work=Sciencemag.com |doi=10.1126/science.aaf4126}} 10. ^{{cite journal | doi = 10.1136/esmoopen-2016-000064| title = Threat posed by unproven drugs in medical oncology |author1=Noam Pondé |author2=Felipe Ades |author3=Evandro de Azambuja | journal = Cancer Horizons | date = 2016 | url = http://esmoopen.bmj.com/content/1/3/e000064 | volume=1 | page=e000064| issue = 3|pmc=5070266}} 11. ^{{cite web|url=http://www.globalpost.com/article/6784886/2016/07/25/human-tests-start-controversial-brazil-cancer-pill |title=Human tests start on controversial Brazil cancer pill |date=25 July 2016 |deadurl=yes |archiveurl=https://web.archive.org/web/20160727153855/http://www.globalpost.com/article/6784886/2016/07/25/human-tests-start-controversial-brazil-cancer-pill |archivedate=2016-07-27 |df= }} Additional images 2 : Amines|Organophosphates |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。